WO2008089772A1 - Formulation of an orodispersible coated tablet containing acetylsalicylic acid - Google Patents
Formulation of an orodispersible coated tablet containing acetylsalicylic acid Download PDFInfo
- Publication number
- WO2008089772A1 WO2008089772A1 PCT/DZ2007/000001 DZ2007000001W WO2008089772A1 WO 2008089772 A1 WO2008089772 A1 WO 2008089772A1 DZ 2007000001 W DZ2007000001 W DZ 2007000001W WO 2008089772 A1 WO2008089772 A1 WO 2008089772A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- orodispersible
- formulation
- salicylates
- acetylsalicylic acid
- tablet containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
Definitions
- the invention relates to the formulation of an orodispersible tablet based on the active ingredient acetylsalicylic acid coated at various dosages
- the active ingredient acetylsalicylic acid of the family of salicylates is known for the following pharmacodynamic properties:
- Analgesia The types of pain usually relieved by salicylate are those of low intensity occurring in the integumentary structures rather than in the viscera, such as headache, myalgia and arthralgia.
- Salicylates rapidly and effectively lower elevated body temperature, although low doses producing this effect increase oxygen uptake and metabolism.At toxic doses, these compounds have a pyrethroid effect causing perspiration; this increase in dehydration occurs during salicylate intoxication.
- Salicylates also cause nausea and vomiting, which result from stimulation of sites that come into contact with cerebrospinal fluid (CSF).
- CSF cerebrospinal fluid
- Salicylates The effects of salicylates on breathing are important because they cause an intense disturbance of the acid-base balance that characterizes intoxication by this class of compounds.
- Salicylates stimulate respiration directly and indirectly.
- Therapeutic doses of salicylates increase oxygen consumption and CO 2 production (especially in skeletal muscle); these effects result from a breakdown of the oxidative phosphorylation reactions
- Acid-base equilibrium and electrolytic balance Therapeutic levels of salicylates produce changes in acid-base balance and ionogram.
- Cardiovascular effects At usual therapeutic doses, salicylates do not have significant direct cardiovascular effects. Peripheral vessels tend to dilate under high doses as a result of a direct effect on their smooth musculature. The toxicity is equivalent to a depression of the circulation by a direct action and a paralysis of the vasomotor center. • Gastrointestinal effects: Ingestion of salicylate may cause epigastric pain, nausea and vomiting. Salicylates can also cause gastric ulceration: exacerbation of the symptoms of a peptic ulcer (dyspepsia, heartburn), gastrointestinal bleeding and an erosive gastritis were observed in patients receiving high doses, but can also occur when lower doses are administered.
- Salicylates can cause at least two forms of liver damage.
- hepatotoxicity is dose-dependent and is usually associated with plasma concentrations that remain above 150 ⁇ g / ml.
- the vast majority of these cases occur in patients with connective tissue disruption. There is usually no symptoms, and the elevation of hepatocellular enzyme activity in plasma is the main sign of liver damage. About 5% of these patients also have hepatomegaly, anorexia, nausea and jaundice; in these circumstances, salicylates should not be prosecuted. Therefore, among other reasons, the limitation of salicylate use is required in patients with chronic liver disease.
- uric acid • Effects on the blood: Aspirin ingestion by healthy individuals causes prolonged bleeding time Aspirin is used in the prophylaxis of thromboembolic disease, especially in the coronary and cerebral circulation .
- Salicylates do not usually cause changes in leukocyte and platelet counts, hematocrit or hemoglobin content. However, doses of 3 to 4 g per day result in a decrease in the iron content of the plasma and a shortening of the life of erythrocytes.
- Aspirin is one of the drugs that can cause moderate haemolysis in patients with impaired glucose-6-phosphate dehydrogenase. Aspirin is one of the drugs that can cause moderate haemolysis in patients with impaired glucose- ⁇ -phosphate dehydrogenase.
- Endocrine Effects Very high doses of salicylate stimulate steroidal secretion of the adrenal cortex via an action on the hypothalamus and a transient increase in plasma concentrations of free adrenal corticosteroids by displacement of their plasma proteins.
- the active ingredient acetyl salicylic acid does not exist in the form orodispersible tablet against it is available in the various other forms: effervescent tablet, chewable tablet, naked tablet, powder for oral solution ....
- the active ingredient: Aspirin or acetylsalicylic acid is known for its hygroscopicity and poor rheological properties (flow and compaction). To overcome these problems, the coating of the active ingredient with a polymer has been achieved to improve its technological properties and appearance and taste
- Acetylsalicylic acid for dosages ranging from 75 to 325 mg is available only in a sachet dose for oral solution requiring water for consumption, which is not practical in the states of crisis and emergency.
- the object of the invention is to formulate an orodispersible tablet based on acetyl salicylic acid coated at various doses by overcoming the range 75 to 325 and using a matrix composed of a mixture of powders based on mannitol, sorbitol, crospovidone and silica with the active ingredient coated.
- the present invention proposes the formulation of an orodispersible tablet based on acetyl salicylic acid coated at dosages: 75 to 325 mg
- the orodispersible tablet formulated is based on active principle
- sorbitol 2-20)% crospovidone, (0.1 to 10)% silica, (1-5)% sodium saccharinate, (0.1-5) mint flavor and (0.5-4) % sodium stearyl fumarate. Since the manufacturing process is conventional, a powder mixture is made by mixing all the raw materials with the exception of the lubricant which is sodium stearyl fumarate for a time sufficient to obtain a homogeneous mixture and then the lubricant is added and a remix is performed for a specified time.
- the lubricant which is sodium stearyl fumarate for a time sufficient to obtain a homogeneous mixture and then the lubricant is added and a remix is performed for a specified time.
Abstract
The invention relates to the formulation of an orodispersible tablet containing acetylsalicylic acid as an active ingredient and coated into different dosages.
Description
FORMULATION D'UN COMPRIME ORODISPERSIBLE A BASE D'ACIDE ACETYLSALICYLIQUE ENROBE FORMULATION OF AN ORODISPERSIBLE TABLET BASED ON ACETYLSALICYLIC ACID ENROBE
Domaine technique auquel se rapporte l'inventionTechnical field to which the invention relates
L'invention concerne la formulation d'un comprimé orodispersible à base du principe actif acide acétylsalicylique enrobé à différents dosages Le principe actif acide acétylsalicylique de la famille des salicylates est connu pour les propriétés pharmacodynamiques suivantes :The invention relates to the formulation of an orodispersible tablet based on the active ingredient acetylsalicylic acid coated at various dosages The active ingredient acetylsalicylic acid of the family of salicylates is known for the following pharmacodynamic properties:
"Analgésie : les types de douleurs habituellement soulagés par le salicylate sont ceux de faible intensité survenant dans les structures tégumentaires plutôt que dans les viscères, comme les céphalées, les myalgies et les arthralgies.Analgesia: The types of pain usually relieved by salicylate are those of low intensity occurring in the integumentary structures rather than in the viscera, such as headache, myalgia and arthralgia.
" Action antipyrétique : Les salicylates abaissent rapidement et efficacement l'élévation de la température corporelle, bien que de faibles doses produisant cet effet accroissent la consommation d'oxygène et le métabolisme. A doses toxiques, ces composés ont un effet pyrétique entraînant une transpiration ; cette augmentation de la déshydratation se produit au cours de l'intoxication salicylée.Antipyretic action: Salicylates rapidly and effectively lower elevated body temperature, although low doses producing this effect increase oxygen uptake and metabolism.At toxic doses, these compounds have a pyrethroid effect causing perspiration; this increase in dehydration occurs during salicylate intoxication.
Effets neurologiques divers : A forte dose, les salicylés provoquent des effets toxiques sur le SNC à type de stimulation (incluant les convulsions) suivie d'une dépression. Confusion, vertiges, bourdonnements d'oreille, surdité pour les sons aigus, psychose, stupeur et coma peuvent se produire.Various neurological effects: In high doses, salicylates cause CNS-toxic effects with stimulation (including seizures) followed by depression. Confusion, dizziness, tinnitus, deafness for high-pitched sounds, psychosis, stupor and coma can occur.
Les salicylates provoquent également des nausées et des vomissements, qui résultent d'une stimulation des sites qui sont en contact avec le liquide céphalorachidien (LCR)Salicylates also cause nausea and vomiting, which result from stimulation of sites that come into contact with cerebrospinal fluid (CSF).
Respiration : Les effets des salicylates sur la respiration sont importants parce qu'ils entraînent une perturbation intense de l'équilibre acido-basique qui caractérise l'intoxication par cette classe de composés. Les salicylates stimulent la respiration directement et indirectement. Les doses thérapeutiques de salicylates
augmentent la consommation d' oxygène et la production de CO2 (tout particulièrement au niveau du muscle squelettique) ; ces effets résultent d'un découpage des réactions de phosphorylation oxydativeBreathing: The effects of salicylates on breathing are important because they cause an intense disturbance of the acid-base balance that characterizes intoxication by this class of compounds. Salicylates stimulate respiration directly and indirectly. Therapeutic doses of salicylates increase oxygen consumption and CO 2 production (especially in skeletal muscle); these effects result from a breakdown of the oxidative phosphorylation reactions
Equilibre acido-basique et bilan électrolytique : Les taux thérapeutiques de salicylates produisent des modifications de l'équilibre acido-basique et de l' ionogramme.Acid-base equilibrium and electrolytic balance: Therapeutic levels of salicylates produce changes in acid-base balance and ionogram.
•Effets cardio-vasculaires : Aux doses thérapeutiques habituelles, les salicylates n'ont pas d'effets cardio- vasculaires directs importants. Les vaisseaux périphériques ont tendance à se dilater sous l'action de fortes doses par suite d'un effet direct sur leur musculature lisse. La toxicité équivaut à une dépression de la circulation par une action directe et par une paralysie du centre vasomoteur. • Effets gastro-intestinaux : L'ingestion de salicylate peut provoquer des douleurs épigastriques, des nausées et des vomissements. Les salicylates peuvent également provoquer une ulcération gastrique : une exacerbation des symptômes d'un ulcère peptique (dyspepsie, brûlure d'estomac), une hémorragie gastro-intestinale et ' une gastrite érosive ont été observées chez les patients recevant des doses élevées, mais peuvent se produire également quand des doses plus faibles sont administrées.• Cardiovascular effects: At usual therapeutic doses, salicylates do not have significant direct cardiovascular effects. Peripheral vessels tend to dilate under high doses as a result of a direct effect on their smooth musculature. The toxicity is equivalent to a depression of the circulation by a direct action and a paralysis of the vasomotor center. • Gastrointestinal effects: Ingestion of salicylate may cause epigastric pain, nausea and vomiting. Salicylates can also cause gastric ulceration: exacerbation of the symptoms of a peptic ulcer (dyspepsia, heartburn), gastrointestinal bleeding and an erosive gastritis were observed in patients receiving high doses, but can also occur when lower doses are administered.
Le saignement gastrique induit par les salicylates est parfois indolore et, s'il n'est pas reconnu, peut entraîner une anémie par déficience en fer. " Effets hépatiques et rénaux : Les salicylates peuvent provoquer au moins deux formes d'atteinte hépatique.Gastric bleeding induced by salicylates is sometimes painless and, if not recognized, may result in iron deficiency anemia. Hepatic and renal effects: Salicylates can cause at least two forms of liver damage.
"Dans une des formes, l' hépatotoxicité est dose-dépendante et est habituellement associée à des concentrations plasmatiques qui se maintiennent au-dessus de 150 μg/ml. La grande majorité de ces cas se produit chez les patients atteints de perturbation du tissu conjonctif. Il n'y a habituellement pas de symptômes, et l'élévation de l'activité des enzymes hépatocellulaires dans
le plasma est le principal signe de l'atteinte hépatique. Environ 5% de ces patients ont aussi une hépatomégalie, une anorexie, des nausées et un ictère; dans ces circonstances, les salicylates ne doivent pas être poursuivis. C'est pourquoi, parmi d'autres raisons, la limitation de l'emploi des salicylates s'impose chez les patients ayant une maladie hépatique chronique. "Effets uriσosuriques : les effets des salicylates sur l'excrétion de l'acide urique sont doses-dépendants. De faibles doses (1 à 2 g par jour) peuvent diminuer l'excrétion des urates et élever les concentrations d' urates dans le plasma ; des doses intermédiaires (2 à 3 g par jour) ne provoquent habituellement pas de modification de l'excrétion des urates ; en revanche, des doses élevées (plus de 5 g par jour) induisent une uricosurie et un abaissement du taux plasmatique d'acide urique. •Effets sur le sang : L'ingestion d'aspirine par les individus sains provoque un allongement du temps de saignement. L'aspirine est utilisée dans la prophylaxie de la maladie thromboembolique, en particulier au niveau de la circulation coronaire et cérébrale."In one form, hepatotoxicity is dose-dependent and is usually associated with plasma concentrations that remain above 150 μg / ml." The vast majority of these cases occur in patients with connective tissue disruption. There is usually no symptoms, and the elevation of hepatocellular enzyme activity in plasma is the main sign of liver damage. About 5% of these patients also have hepatomegaly, anorexia, nausea and jaundice; in these circumstances, salicylates should not be prosecuted. Therefore, among other reasons, the limitation of salicylate use is required in patients with chronic liver disease. "Uriσosuric effects: the effects of salicylates on the excretion of uric acid are dose-dependent Low doses (1-2 g per day) may decrease urate excretion and elevate urate levels in plasma Intermediate doses (2 to 3 g daily) do not usually cause changes in urate excretion, whereas high doses (> 5 g / day) induce uricosuria and lower plasma levels. uric acid • Effects on the blood: Aspirin ingestion by healthy individuals causes prolonged bleeding time Aspirin is used in the prophylaxis of thromboembolic disease, especially in the coronary and cerebral circulation .
Les salicylates ne provoquent habituellement pas d'altération du nombre des leucocytes et des plaquettes, ni de l' hématocrite ou de la teneur en hémoglobine. Pourtant, des doses de 3 à 4 g par jour entraînent une diminution de la teneur en fer du plasma et un raccourcissement de la durée de vie des érythrocytes . L'aspirine fait partie des médicaments qui peuvent provoquer une hémolyse modérée chez les patients atteints d'une déficience en glucose-6-phosphate-déshydrogénase. L'aspirine fait partie des médicaments qui peuvent provoquer une hémolyse modérée chez les patients atteints d'une déficience en glucose-β-phosphate-déshydrogénase.Salicylates do not usually cause changes in leukocyte and platelet counts, hematocrit or hemoglobin content. However, doses of 3 to 4 g per day result in a decrease in the iron content of the plasma and a shortening of the life of erythrocytes. Aspirin is one of the drugs that can cause moderate haemolysis in patients with impaired glucose-6-phosphate dehydrogenase. Aspirin is one of the drugs that can cause moderate haemolysis in patients with impaired glucose-β-phosphate dehydrogenase.
"Effets sur le rhumatisme, l'inflammation, les processus immunologiques et le métabolisme du tissu conjonctif : depuis plus de 100 ans, les salicylates occupent une position prédominante dans le domaine du traitement des maladies
rhumatismales. Bien qu'ils suppriment les signes cliniques et améliorent également les signes histologiques de la fièvre rhumatismale aiguë, les lésions tissulaires qui en découlent comme les lésions cardiaques et d'autres viscères ne sont pas modifiés. En plus de leur action sur la biosynthèse des prostaglandines, le mécanisme d'action des salicylates sur les maladies rhumatismales entraine aussi des actions sur d'autres cellules et processus immunologiques dans les tissus mésenchymateux et conjonctif."Effects on Rheumatism, Inflammation, Immunological Processes and Connective Tissue Metabolism: For over 100 years, salicylates have dominated the field of disease treatment Rheumatic. Although they suppress the clinical signs and also improve the histological signs of acute rheumatic fever, the resulting tissue lesions such as heart lesions and other viscera are not altered. In addition to their action on the biosynthesis of prostaglandins, the mechanism of action of salicylates on rheumatic diseases also involves actions on other cells and immunological processes in the mesenchymal and connective tissues.
• Effets métaboliques : Les salicylates ont de multiples effets sur les processus métaboliques, parmi lesquels certains ont déjà été décrits à savoir :• Metabolic effects: Salicylates have multiple effects on metabolic processes, some of which have already been described namely:
' Phosphoxγlation oxydat±ve " Métabolisme des glucides » Métabolisme de l'azote " Métabolisme lipidique'Oxidative Phosphoxγlation' Carbohydrate Metabolism 'Nitrogen Metabolism' Lipid Metabolism
" Effets endocriniens : de très fortes doses de salicylate stimulent la sécrétion stéroïdienne du cortex surrénalien par l'intermédiaire d'une action sur l'hypothalamus et une augmentation transitoire des concentrations plasmatiques de corticoïdes surrénaliens libres par déplacement de leur protéines plasmatiques. La présente invention concerne la formulation d'un comprimé à base d' acide acétyle salicylique enrobé utilisant une matrice de désintégration rapide pharmaceutiquement acceptable qui permet la désagrégation rapide du comprimé dans la cavité buccale. Sachant que le meilleur rapport bénéfices/risques de l'acide acétyle salicylique est obtenu avec des doses quotidiennes de 75 à 350 mg, la présente invention concerne ce domaine dosages.Endocrine Effects: Very high doses of salicylate stimulate steroidal secretion of the adrenal cortex via an action on the hypothalamus and a transient increase in plasma concentrations of free adrenal corticosteroids by displacement of their plasma proteins. relates to the formulation of a coated acetyl salicylic acid based tablet utilizing a pharmaceutically acceptable fast disintegrating matrix which allows rapid disintegration of the tablet in the oral cavity.We know that the best benefit / risk ratio of acetyl salicylic acid is obtained with daily doses of 75 to 350 mg, the present invention relates to this field assays.
Etat de la technique antérieureState of the art
Le principe actif acide acétyle salicylique n'existe pas sous la forme comprimé orodispersible par contre il est disponible sous les différentes autres formes : comprimé effervescent, comprimé à croquer, comprimé nu, poudre pour solution buvable....
Le principe actif : Aspirine ou l'acide acétylsalicylique est connue pour son hygroscopicité et ses mauvaises propriétés rhéologiques (écoulement et tassement) . Pour palier à ces problèmes, l'enrobage du principe actif avec un polymère a été réalisé afin d'améliorer ses propriétés technologiques ainsi que l'aspect et le goûtThe active ingredient acetyl salicylic acid does not exist in the form orodispersible tablet against it is available in the various other forms: effervescent tablet, chewable tablet, naked tablet, powder for oral solution .... The active ingredient: Aspirin or acetylsalicylic acid is known for its hygroscopicity and poor rheological properties (flow and compaction). To overcome these problems, the coating of the active ingredient with a polymer has been achieved to improve its technological properties and appearance and taste
L'acide acétylsalicylique pour les dosages allant de 75 à 325 mg existe uniquement en sachet dose pour solution buvable nécessitant de l'eau pour sa consommation, ce qui n'est pas pratique dans les états de crise et d'urgence.Acetylsalicylic acid for dosages ranging from 75 to 325 mg is available only in a sachet dose for oral solution requiring water for consumption, which is not practical in the states of crisis and emergency.
But de l'inventionPurpose of the invention
Le but de l'invention est de formuler un comprimé orodispersible à base d'acide acétyle salicylique enrobé à différents dosages en palliant le domaine 75 à 325 et ce en utilisant une matrice composée d'un mélange de poudres à base de mannitol, sorbitol, crospovidone et de silice avec le principe actif enrobé.The object of the invention is to formulate an orodispersible tablet based on acetyl salicylic acid coated at various doses by overcoming the range 75 to 325 and using a matrix composed of a mixture of powders based on mannitol, sorbitol, crospovidone and silica with the active ingredient coated.
Présentation de l'essence (la substance) de l'invention La présente invention propose la formulation d'un comprimé orodispersible à base d'acide acétyle salicylique enrobé aux dosages : 75 à 325 mg Le comprimé orodispersible formulé est à base de principe actifPresentation of the essence (the substance) of the invention The present invention proposes the formulation of an orodispersible tablet based on acetyl salicylic acid coated at dosages: 75 to 325 mg The orodispersible tablet formulated is based on active principle
(acide acétyle salicylique enrobé) , (50-80) % de mannitol, (20-(coated acetyl salicylic acid), (50-80)% mannitol, (20-
30) % de sorbitol, (2-20) % de crospovidone, (0.1 à 10) % de silice, (1-5) % de saccharinate de sodium, (0.1-5) d'arôme menthe et (0.5-4) % de stéaryle fumarate de sodium. Le procédé de fabrication étant classique, un mélange de poudre est effectué en mélangeant la totalité des matières premières à l'exception du lubrifiant qui est le stéaryle fumarate de sodium pendant un temps suffisant pour l'obtention d'un mélange homogène puis le lubrifiant est rajouté et un remélange est effectué pendant un temps indiqué.
30)% sorbitol, (2-20)% crospovidone, (0.1 to 10)% silica, (1-5)% sodium saccharinate, (0.1-5) mint flavor and (0.5-4) % sodium stearyl fumarate. Since the manufacturing process is conventional, a powder mixture is made by mixing all the raw materials with the exception of the lubricant which is sodium stearyl fumarate for a time sufficient to obtain a homogeneous mixture and then the lubricant is added and a remix is performed for a specified time.
Claims
1. La forme comprimé orodispersible appliquée au principe actif acide acétyle salicylique enrobé au dosages 75 à 325 mg.1. The orodispersible tablet form applied to the active ingredient acetyl salicylic acid coated at 75 to 325 mg.
2. Composition pharmaceutique selon la revendication 1 caractérisée en ce qu'elle se présente sous forme des comprimés orodispersibles .2. Pharmaceutical composition according to claim 1 characterized in that it is in the form of orodispersible tablets.
3. La formule de fabrication selon la revendication 2 qui est à base d'une matrice composée d'un mélange de poudres composé de mannitol, sorbitol, crospovidone et silice, (permettant la désintégration rapide) .3. The manufacturing formula according to claim 2 which is based on a matrix composed of a mixture of powders composed of mannitol, sorbitol, crospovidone and silica, (allowing rapid disintegration).
4. Composition pharmaceutique selon la revendication 3 caractérisée en ce qu'elle comprend également un ou plusieurs édulcorant un lubrifiant et un arôme.4. Pharmaceutical composition according to claim 3 characterized in that it also comprises one or more sweetener a lubricant and a flavor.
5. Comprimés orodispersibles selon la revendication 4 caractérisés en ce qu'ils sont obtenus par compression directe. 5. orodispersible tablets according to claim 4 characterized in that they are obtained by direct compression.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/DZ2007/000001 WO2008089772A1 (en) | 2007-01-22 | 2007-01-22 | Formulation of an orodispersible coated tablet containing acetylsalicylic acid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/DZ2007/000001 WO2008089772A1 (en) | 2007-01-22 | 2007-01-22 | Formulation of an orodispersible coated tablet containing acetylsalicylic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2008089772A1 true WO2008089772A1 (en) | 2008-07-31 |
Family
ID=38608895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/DZ2007/000001 WO2008089772A1 (en) | 2007-01-22 | 2007-01-22 | Formulation of an orodispersible coated tablet containing acetylsalicylic acid |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2008089772A1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2766089A1 (en) * | 1997-07-21 | 1999-01-22 | Prographarm Lab | IMPROVED MULTIPARTICULAR TABLET WITH RAPID DELIVERY |
| FR2785538A1 (en) * | 1998-11-06 | 2000-05-12 | Prographarm Laboratoires | PERFECTED QUICK DELIVERY TABLET |
| FR2790387A1 (en) * | 1999-03-01 | 2000-09-08 | Prographarm Laboratoires | ORODISPERSIBLE TABLET WITH LOW FRIABILITY AND ITS PREPARATION PROCESS |
| WO2003051338A1 (en) * | 2001-12-17 | 2003-06-26 | Spi Pharma, Inc. | Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms |
-
2007
- 2007-01-22 WO PCT/DZ2007/000001 patent/WO2008089772A1/en active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2766089A1 (en) * | 1997-07-21 | 1999-01-22 | Prographarm Lab | IMPROVED MULTIPARTICULAR TABLET WITH RAPID DELIVERY |
| FR2785538A1 (en) * | 1998-11-06 | 2000-05-12 | Prographarm Laboratoires | PERFECTED QUICK DELIVERY TABLET |
| FR2790387A1 (en) * | 1999-03-01 | 2000-09-08 | Prographarm Laboratoires | ORODISPERSIBLE TABLET WITH LOW FRIABILITY AND ITS PREPARATION PROCESS |
| WO2003051338A1 (en) * | 2001-12-17 | 2003-06-26 | Spi Pharma, Inc. | Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20190014798A1 (en) | Hydroxybutyrate ester and medical use thereof | |
| AU2009283171B2 (en) | Hydroxybutyrate ester and medical use thereof | |
| WO1998007417A1 (en) | Pharmaceutical composition comprising coenzyme q¿10? | |
| KR20160120785A (en) | Method of producing physiological and therapeutic levels of nitric oxide through an oral delivery system | |
| US20210094900A1 (en) | Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds | |
| EP0336851A1 (en) | Pharmaceutical composition for oral administration containing a diphosphonic acid derivative | |
| JP2001513487A (en) | Composition for treating diabetes and treatment method | |
| CA2203310C (en) | Compressed matrix for slow release of salt of tianeptine sodium following oral administration | |
| NZ560990A (en) | Compositions for oral transmucosal delivery of metformin | |
| EP1549326A1 (en) | Dry oral phlebotonic and vasculoprotective formulation for the treatment of venous insufficiency, capillary fragility and haemorrhoids, in the pharmaceutical form of a chewable tablet containing diosmin | |
| LU83869A1 (en) | PROCESS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION COMPRISING GAMMA-BUTYROBETAIN FOR THE TREATMENT OF SYNDROMAS CAUSED BY L-CARMITINE DEFICIENCY | |
| EP0954298B1 (en) | 2,5-dihydroxybenzenesulfonic derivatives for the treatment of sexual dysfunction | |
| JP2012513454A (en) | Formulation for oral mucosal administration of lipid-lowering drugs | |
| BE1016128A6 (en) | Combination therapy | |
| WO2008089772A1 (en) | Formulation of an orodispersible coated tablet containing acetylsalicylic acid | |
| EP3100737A1 (en) | Dietary supplement comprising a mixture of magnesium oxide and magnesium carbonate | |
| EP1870095A1 (en) | Composition for increasing anti-oxidation activity in blood | |
| FR2580497A1 (en) | PHARMACEUTICAL COMPOSITIONS IN COMPRESSES | |
| JPS6341421A (en) | Anticataract agent | |
| BE1005939A6 (en) | Use of orotic acid salts as preferential trace element carriers | |
| EP0483320B1 (en) | Slow release pharmaceutical compositions to be orally administered, and method for preparing same | |
| KR20050050671A (en) | Enhancement of alcohol metabolism | |
| RU2331413C1 (en) | Solid dosage drug formulation, increasing physical and mental performance | |
| BE1001465A3 (en) | Antiasthenic COMPOSITION, METHOD OF PREPARATION AND USE. | |
| US20050215644A1 (en) | Methods for increasing neurotransmitter levels using hydroxycitric acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07702538 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 07702538 Country of ref document: EP Kind code of ref document: A1 |